| Ytd | -16.13% | |
| 1y | -29.03% |
| Open | 14.26 | Prev Close | 14.07 | Low | 13.63 | High | 14.38 | Mkt Cap | 521.08M |
| Vol | 133.07K | Avg Vol | 798.04K | EPS | -10.14 | P/E | -1.42 | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 16.07 | 200-d Avg | 20.52 | 1yr Est | 0.00 |
EVMN News
Evommune, Inc. (NYSE: EVMN - Get Free Report) has been given a consensus recommendation of "Moderate
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
PALO ALTO, Calif., & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evomm
Evommune stock dropped approximately 38% after EVO756 missed its Phase 2b primary endpoint in chroni
Evommune, Inc.'s recent miss with EVO756's CSU indications is a major setback. I agree that this cre
Evommune's CEO and CSO sold shares on June 22, 2026, under Rule 10b5-1 plans adopted months earlier
Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the compan
Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 284.8% to $11.39 during Monday
Read Also: Evommune Stock Cools Off After Big Rally On Successful Eczema Trial
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 200 poi
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (the “Company” or “Evommu
US stock futures up, Nasdaq 100 gains 1%. Biohaven (BHVN) shares down after BofA downgrade and enrol
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
Evommune, Inc. (EVMN) Discusses Scientific Rationale and Pipeline Expansion for MRGPRX2 Antagonist i
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
Capricorn Fund Managers Ltd acquired a new stake in Evommune, Inc. (NYSE: EVMN) in the fourth quarte
Top analysts changed outlook on top names. Mizuho, Needham, Rothschild & Co, HC Wainwright &
Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S
Shares of Evommune, Inc. (NYSE: EVMN - Get Free Report) have been assigned an average rating of "Mod
Clinical-stage biotech Evommune is seen as a potential buyout candidate. Its shares are up more than
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (NYSE: EVMN) (“Evommune” or the “Compa
Evommune, Inc. (NYSE: EVMN - Get Free Report) has earned a consensus rating of "Moderate Buy" from t
PALO ALTO, Calif. & NEW YORK--(BUSINESS WIRE)--Evommune, Inc. (“Evommune” or the “Company”) (NYSE: E
Evommune, Inc. (NASDAQ: EVMN) shares are trading lower on Thursday on profit-taking after the stock
The 70-patient trial was designed to evaluate the safety and efficacy of intravenous dosing of 5mg/k
